Floatz logo

Therapeutic Asset Ratings

3,848 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Chimeric Antigen Receptor Modified T Cells Infusion
Non Hodgkin Lymphoma
University of Texas Southwestern Medical CenterP2BB (67)
Axicabtagene Ciloleucel
Recurrent Diffuse Large B-Cell Lymphoma
Zhujiang HospitalP3BB (66)
Axicabtagene Ciloleucel
Refractory Non-Hodgkin Lymphoma
Lyell Immunopharma, Inc.P3BB (66)
Axicabtagene Ciloleucel
Relapsed Non-Hodgkin Lymphoma
Lyell Immunopharma, Inc.P3BB (66)
CART-ddBCMA
De Novo Multiple Myeloma
PETHEMA FoundationP3BB (66)
Jcar017 (Lisocabtagene Maraleucel)
Lymphoma, Large B-Cell, Diffuse
Lyell Immunopharma, Inc.P3BB (66)
Lifileucel
Metastatic Cutaneous Melanoma
Vastra Gotaland RegionP3BB (66)
Lifileucel
Unresectable Melanoma
Iovance Biotherapeutics, Inc.P3BB (66)
Nrtx-1001
Epilepsy, Temporal Lobe
Neurona TherapeuticsP3BB (66)
Nurown Msc-Ntf Cells
Amyotrophic Lateral Sclerosis
Brainstorm-Cell TherapeuticsP3BB (66)
Sipuleucel-T
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
City of Hope Medical CenterP3BB (66)
Sipuleucel-T
Prostate Cancer
City of Hope Medical CenterP3BB (66)
Tabelecleucel
Allogeneic Hematopoietic Cell Transplant
Pierre Fabre MedicamentP3BB (66)
Tabelecleucel
EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)
Pierre Fabre MedicamentP3BB (66)
Tabelecleucel
Solid Organ Transplant Complications
Pierre Fabre MedicamentP3BB (66)
Tabelecleucel
Stem Cell Transplant Complications
Pierre Fabre MedicamentP3BB (66)
Tisagenlecleucel
Non-Hodgkin Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.P3BB (66)
cd7.car/28zeta car t cells
T-non-Hodgkin Lymphoma
Baylor College of MedicineP2BB (66)
Chimeric Antigen Receptor Modified T Cells Infusion
B-cell Acute Lymphoblastic Leukemia
Shenzhen Geno-Immune Medical InstituteP2BB (66)
Chimeric Antigen Receptor Modified T Cells Infusion
Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
Peking University People's HospitalP2BB (66)
Nk Cell
Acute Myeloid Leukaemia (AML)
Hospital de Clinicas de Porto AlegreP2BB (66)
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs
MDS
Fred Hutchinson Cancer CenterP2/3BB (66)
HUMAN CULTURE EXPANDED GENETICALLY MODIFIED AUTOLOGOUS T CELLS FOR CELL-BASED GENE THERAPY. CELLS ARE DERIVED FROM ISOLATED BLOOD OF THE PATIENT AND ARE TRANSDUCED WITH NON-REPLICATIVE SELF-INACTIVATING (SIN) HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) BASED LENTIVIRAL VECTOR (LVV) PSEUDOTYPED WITH THE VESICULAR STOMATITIS VIRUS GLYCOPROTEIN G (VSV-G) ENVELOPE PROTEIN, AND ENCODING THE C11D5.3 ANTI-TNF RECEPTOR SUPERFAMILY MEMBER 17 (TNFRSF17, BCMA) SINGLE CHAIN VARIABLE FRAGMENT (SCFV) CD8/4-1BB/CD3ZETA CHIMERIC ANTIGEN RECEPTOR (CAR) UNDER THE TRANSCRIPTIONAL CONTROL OF THE MYELOPROLIFERATIVE SARCOMA VIRUS ENHANCER, NEGATIVE CONTROL REGION DELETED, DL587REV PRIMER-BINDING SITE SUBSTITUTED (MND) PROMOTE
Multiple Myeloma
Memorial Sloan Kettering Cancer CenterP3BB (65)
Jcar017 (Lisocabtagene Maraleucel)
Lymphoma, Non-Hodgkin
Lyell Immunopharma, Inc.P3BB (65)
Jcar017 (Lisocabtagene Maraleucel)
Grade 3b Follicular Lymphoma
Fred Hutchinson Cancer CenterP2BB (65)
Showing 26 to 50 of 3,848 assets
PreviousPage 2 of 154Next